Spinal cord infarction is a rare but often devastating disorder caused by disruption in the vascular spinal supply. We report a patient with spinal cord infarction associated with lenalidomide therapy for primary amyloidosis, in the background of other predisposing factors. We describe the clinical case and discuss the possible explanation for this rare complication. As spinal cord infarction is not a known complication of lenalidomide therapy or amyloidosis, this description raises the potential of such a side effect in some certain conditions and discusses the role of the old and new anticoagulant agents in prevention of thromboembolic complications in high-risk patients.
Introduction
Spinal cord infarction is a rare but often devastating disorder, accounting for only 1% of all strokes and caused by prolapse. However most cases were idiopathic [1] [2] . We report for the first time a patient with primary AL amyloidosis who developed spinal cord infarction associated with lenalidomide therapy in the background of other risk factors and possibly sub-optimal thromboprophylaxis.
Case Report
A 72-years-old man with primary AL Lambda light chain amyloidosis of 5 years duration presented with acute left leg monoplegia accompanied by hypoesthesia and urinary incontinence without back pain. He was a smoker and had known right leg weakness related to poliomyelitis in childhood. Manifestations of amyloidosis included skeletal amyloidomas, renal (proteinuria, 700 mg/24h) and cardiac involvement with intraventricular septum hypertrophy and mild cardiac failure. Four years earlier, he had spinal cord compression with left leg flaccid paralysis and right leg hypoesthesia, related to a T4 vertebral biopsy proven amyloidoma. He was treated with irradiation (T3-T10 bodies, 3 Gy × 10) and a few months later were able to move his legs against gravity. He was also treated with melphalan, prednisone and thalidomide, discontinued because of peripheral neuropathy and replaced by melphalan, dexamethasone and lenalidomide for a year. 
Discussion
Our patient presented with acute left leg weakness while on lenalidomide for primary AL amyloidosis. The clinical presentation, together with the imaging findings strongly suggested acute spinal cord infarction at a previously nonirradiated T11-L1 segment.
Lenalidomide is an immunomodulatory (IMiD) derivative of thalidomide that down-regulates interleukin-6 and nuclear factor κ-B, and activates caspase 8 in vitro [4] , with a known prothrombotic activity due to tumor necrosis factor alpha (TNFα) upregulation, endothelial cell dysfunction and thrombospondin downregulation leading to a cytokine-mediated and activated protein C resistance [5] . Reported lenalidomide-related thromboembolic complications are mostly venous, such as DVT and pulmonary embolism, while arterial events such as cerebrovascular ischemia are less common. Spinal arterial ischemia was not reported previously in association to lenalidomide. Similar to thalidomide, the risk for thrombotic complications is increased when treatment is combined with corticosteroids or chemotherapy, and thromboprophylaxis decreases their incidence [6] [7] . While low molecular weight heparin (LMWH) was proven to be effective in prevention of IMid related thromboembolism [8] , the use of direct oral anticoagulants (DOACs) in prevention of IMiD related thromboembolism is not well established. A small retrospective series [9] found it to be safe and effective; however, it is still investigational and should be reconsidered in high risk patients. Our case again demonstrates the risk in treatment with DOACs for thromboprophylaxis in high risk patients on IMiDs.
Our patient had primary AL amyloidosis, implicated in thrombogenesis through several mechanisms.
Hypercoagulability in amyloidosis is induced by nephrotic syndrome resulting in imbalance of antithrombotic and prothrombotic factors involved in the coagulation cascade [10] . Cardiac thrombi are caused by restrictive cardiomyopathy and frequent arrhythmia due to the amyloid deposition [11] . However, neither arrhythmia nor thrombi were found in our patient. Some patients also develop hyposplenism with thrombocytosis or, infrequently, blood hyperviscosity or circulating monoclonal procoagulant activity [11] , which are also irrelevant in our patient.
Therapeutic immunomodulation may further add thrombotic complications [6] [7] . Most ischemic events in primary amyloidosis are cerebrovascular of cardioembolic source, while peripheral arterial, mesenteric and optic nerve events are less common [11] . Spinal cord infarction was not reported, to our knowledge, in this clinical setup.
Our patient had a T11-L1 spinal cord infarction, an uncommon location among ischemic spinal events. This segment is supplied by a branch of the intercostal artery arising between T8 and L1, called Adamkiewicz artery [2] . Since previous radiation fields in our patient included these segments, it is possible that Adamkiewicz artery was exposed, predisposing it to radiation-induced accelerated atherosclerosis [12] with a risk for ischemia in its territory. Because no spinal angiogram was performed, we could not confirm this possibility. It should be noted that our patient was a smoker, thus rendering him high risk for arterial occlusion and thrombosis. However, spinal cord ischemia was reported to be rare even among patients with cardiovascular risk factors [13] .
Taken together, it seems likely that our patient manifested lenalidomide-related spinal cord infarction on the background of multiple predisposing factors, including smoking, AL amyloidosis, and, possibly, accelerated radiation-induced atherosclerosis, combined with sub-optimal thromboprophylaxis due to exchanging enoxaparin with rivaroxaban. Re-treatment with lenalidomide after the patient had been well anticoagulated by enoxaparin was
Conclusion
Spinal cord infarction is a rare ischemic manifestation, even among patients with cardiovascular risk factors. It was not previously reported in relation to neither amyloidosis nor lenalidomide treatment. However, this rare complication should be considered in the differential diagnosis in the appropriate clinical context among patients treated by lenalidomide, especially when other risk factors co-exist. In the face of the widespread use of DOACs, we suggest that for high risk patients receiving lenalidomide, LMWH should still be considered as the optimal agent for thromboprophylaxis.
